AACR21: iTeos busts out ear­ly hu­man da­ta for an­ti-TIG­IT an­ti­body. Is it enough to match up with Roche, Mer­ck?

The TIG­IT pro­tein has turned in­to an arms race for Big Phar­ma, with Mer­ck and Roche look­ing to add their own can­di­dates to check­point in­hibitor com­bos. A small­er play­er in that race, iTeos Ther­a­peu­tics, is one step be­hind those big names and is rolling out ear­ly da­ta that looks pret­ty par for the course.

iTeos’ an­ti-TIG­IT im­mune re­cep­tor an­ti­body EOS-448 post­ed one con­firmed par­tial re­sponse and churned up no sur­pris­ing safe­ty sig­nals in the dose-es­ca­la­tion, monother­a­py por­tion of a Phase I/IIa study in pa­tients with ad­vanced sol­id tu­mors, ac­cord­ing to da­ta pre­sent­ed Sat­ur­day at the vir­tu­al AACR an­nu­al meet­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER